Redeye: Moberg Pharma Q1’23 - EU Approval on the horizon
Redeye sees a relatively uneventful report with some positive highlights with continued progress in the EU regulatory process and the Phase 3 study in the US going ahead at full speed as it is the high season for the product. Moberg Pharma is progressing as planned, and the EU approval should be an important catalyst as we advance.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/